Evaluation of ERRFI1 +808 T/G variant and its mRNA expression in coronary artery in-stent restenosis

Abstract

BackgroundOne of the common treatments in cardiovascular disease as the first cause of death in the world is stent implantation. In-Stent Restenosis (ISR) is the major drawback of stent implantation. As there are several lines of evidence suggesting genetic factors involved in ISR, in this study we evaluated the potential role of +808T/G polymorphism in ERRFI1 and its quantitative expression in the development of ISR. Material and methodsIndividuals with ISR (n = 41) cases and Non-ISR (n = 51) controls, participated in this study. ERRFI1 gene expression in fresh un-stimulated PBMCs was determined in each group using quantitative real-time PCR. DNA extraction from the whole blood was performed using the phenol-chloroform method. The frequency of genotypes was determined by the PCR-RFLP technique. ResultsIn spite of the higher amount of ERRFI1 expression in the control group (non-ISR), there were no statistically significant differences between ISR and non-ISR groups (p > 0.05). The expression of ERRFI1 was significantly different between ISR and Non-ISR groups only in patients with diabetes (p < 0.05). A significant association was observed between +808T/G variant and ISR in patients with metabolic syndrome (p < 0.05). ConclusionsThe result of this study is suggesting that ERRFI1 gene expression may be associated with ISR in patients with diabetes. Therefore, ERRFI1 can be regarded as a target gene for therapeutic approaches. In addition, our data suggest a protective role for ERRFI1+808 T/G variant in the development of ISR in patients with metabolic syndrome.